Moreover, MYL has its quarterly CC yesterday, on which executives continued to talk a big game with respect to Copaxone. Although not new info, such talk could be inducing some investors to sell (or avoid buying) MNTA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”